Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Canada Goose Q2 Fiscal 2026 Earnings Call - Direct-to-Consumer Strength Drives Growth Amid Wholesale Stability
Canada Goose reported a mixed second quarter with robust momentum in its direct-to-consumer (D2C) channel offset by stable yet slightly softer wholesale revenue. The company marked 10 consecutive mont...
- Direct-to-consumer comparable sales grew 10% year-over-year, marking 10 consecutive months of positive comps.
- D2C revenue increased 21%, driven by new product introductions representing about 40% of D2C sales versus 10% last year.
- Wholesale revenue declined 5% in Q2 and 3% year-to-date, reflecting a deliberate scaling back and focus on brand elevation and inventory health.
- +12 more takeaways
Americold Realty Trust Q3 2025 Earnings Call - Navigating Challenging Demand and Capacity Pressures with Strategic Focus on Market Share and Long-term Growth
Americold Realty Trust reported Q3 2025 results in line with expectations despite ongoing headwinds from lower consumer demand and an influx of speculative capacity. CEO Rob Chambers emphasized the st...
- Americold delivered Q3 2025 AFFO per share of $0.35, meeting expectations amid industry headwinds.
- The company’s portfolio is diversified across four cold chain nodes: production-attached, four distribution centers, retail distribution centers, and port facilities.
- Production-attached facilities (30% capacity/revenue) have long-term fixed commitments and high economic occupancy, representing a strategic growth area.
- +12 more takeaways
Albemarle Corporation Q3 2025 Earnings Call - Strong Operational Execution Amidst Lithium Pricing Pressure
Albemarle reported solid third-quarter 2025 results highlighted by record lithium production, disciplined cost controls, and strong free cash flow generation despite a challenging lithium pricing envi...
- Albemarle delivered $1.3 billion in net sales and $226 million adjusted EBITDA, a 7% increase despite lower lithium prices.
- Energy storage sales volumes outperformed with record integrated lithium conversion production and higher spodumene sales.
- The company generated $356 million in cash from operations in Q3, a 57% year-over-year increase due to cost discipline and higher EBITDA.
- +12 more takeaways
BCE Q3 2025 Earnings Call - Accelerating Fiber Growth and AI-Powered Solutions Drive Long-Term Strategy
BCE’s Q3 2025 results underscore strong execution of a newly unveiled three-year strategic plan centered on fiber expansion, wireless innovation, AI-powered enterprise solutions, and digital media gro...
- BCE unveiled a three-year strategic plan focusing on fiber, wireless, AI-powered solutions, and digital media growth.
- Ziply Fiber acquisition (starting August 1) exceeds initial investment case, adding 65,000 fiber subscribers in Q3 including U.S. operations.
- Ziply Fiber’s fiber footprint reaches 1.4 million homes now, targeting 3 million by 2028 and 8 million through partnership expansion over time.
- +13 more takeaways
Smith Micro Software Q3 2025 Earnings Call - Strategic Cost Cuts Accelerate Trajectory Toward Profitability in Mid-2026
Smith Micro Software’s third quarter 2025 results reveal a company in the midst of decisive transformation. Revenue slipped 6% year-over-year to $4.3 million, slightly missing guidance due to delayed ...
- Q3 2025 revenue stood at $4.3 million, down 6% year-over-year and slightly below guidance due to delayed carrier contract finalizations.
- Smith Micro executed strategic cost reductions saving approximately $7.2 million annually by reducing workforce by about 30%.
- The company aims for profitability by mid-2026, bolstered by cost realignment and operational efficiencies.
- +9 more takeaways
Haemonetics Corporation Q2 2026 Earnings Call - Strong Core Growth and Margin Expansion Amid Portfolio Transitions
Haemonetics reported a mixed quarter with reported revenue down 5% due to portfolio transitions but delivered solid 9% organic growth excluding those effects. Blood management technologies and plasma ...
- Reported Q2 revenue was $327 million, down 5% due primarily to last year’s portfolio transitions; organic growth excluding CSL and divestitures was 9%.
- Adjusted EPS rose 13% in Q2 to $1.27, with adjusted operating margins reaching a record 26.7%, driven by margin expansion across all segments.
- Blood management technologies delivered double-digit growth (12% Q2), powered by higher TEG disposable utilization and global launch of the heparinase neutralization cartridge.
- +13 more takeaways
Backblaze Q3 2025 Earnings Call - Strong Growth Drive with AI-Focused Cloud Storage and Go-to-Market Overhaul
Backblaze's Q3 2025 results showcased a solid 14% overall revenue growth, with B2 Cloud Storage leading at 28%, fueled by AI workload adoption. The company beat guidance on revenue and adjusted EBITDA...
- Backblaze delivered a 14% year-over-year revenue growth in Q3 2025, surpassing the high end of guidance.
- B2 Cloud Storage revenue grew 28% year-over-year, driven largely by AI-related workloads and expanding customer base.
- The company is on track to achieve adjusted free cash flow positivity in Q4 2025 with improved adjusted EBITDA margin reaching 23%.
- +12 more takeaways
Moderna Third Quarter 2025 Earnings Call - Advancing mRNA Portfolio Amid Revenue Pressures and Strong Cost Discipline
Moderna reported $1 billion in third quarter 2025 revenue, principally driven by COVID vaccines Spikevax and mNEXSPIKE, alongside RSV vaccine Arazvia. Despite a net loss of $200 million, the company h...
- Moderna reported $1 billion revenue in Q3 2025, mainly from COVID vaccines Spikevax, mNEXSPIKE, and RSV vaccine Arazvia.
- Net loss totaled $200 million due to lower COVID vaccine demand, down from prior year net income of $13 million.
- Significant cost reduction achieved: 34% decrease in cost of sales, R&D, and SG&A year-over-year, and $2.1 billion cost improvement over last four quarters.
- +7 more takeaways
Zai Lab Q3 2025 Earnings Call - Rapid Global Pipeline Advances Offset by Slower Commercial Growth in China
Zai Lab reported a 14% year-over-year revenue growth to $116 million in Q3 2025, underpinned by solid commercial performance in China, led by Vyvgart and Nuzyra. The company emphasized its shift towar...
- Zai Lab's total revenue for Q3 2025 was $116 million, up 14% year-over-year, driven mainly by Nuzyra, Vyvgart, and others.
- Josie (ZL1310), an anti-DLL3 ADC, showed a 68% overall response rate and 94% disease control rate in phase I trials in extensively pretreated small cell lung cancer patients, including strong intracranial activity.
- Josie demonstrated a favorable safety profile with only 13% grade 3 or higher treatment-related adverse events at the optimal dose, far below competitive ADCs, with no treatment-related discontinuations or deaths.
- +7 more takeaways
REGENXBIO Q3 2025 Earnings Call - Advancing Gene Therapies Toward Regulatory Milestones and Commercial Readiness
REGENXBIO delivered strong progress across its gene therapy pipeline in Q3 2025, highlighted by the completion of enrollment in the pivotal RGX-202 Duchenne muscular dystrophy trial and confidence in ...
- Completed enrollment in the pivotal RGX-202 Duchenne muscular dystrophy trial, targeting early Q2 2026 top-line data and mid-2026 BLA submission under accelerated approval.
- RGX-202 features a novel microdystrophin construct with the CT domain and an immune suppression regimen enabling high-dose delivery and a favorable safety profile with no SAEs observed.
- Confirmatory trial for RGX-202 has commenced enrollment post-pivotal study, with sufficient drug supply available and plans for broad ambulatory patient inclusion.
- +12 more takeaways